search

Active clinical trials for "Angioid Streaks"

Results 1-6 of 6

Intravitreal Bevacizumab in Agioid Streaks

Angioid StreaksChoroidal Neovascularization

The purpose of this study is to investigate the safety and efficacy of intravitreal bevacizumab in patients with choroidal neovascularization associated with angioid streaks.

Completed6 enrollment criteria

Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization...

Choroidal Neovascularization in Angioid Streaks

Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations. They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis. Choroidal neovascularization (CNV) represents the most frequent complication for those patients. It leads to a rapid and important loss of visual acuity. CNV in angioid streaks represent the fourth leading cause of CNV in young patients. CNV in angioid streaks is treated at the moment with off-label anti-VEGF (Vascular Endothelial Growth Factor) therapy and could also benefit from aflibercept (EYLEA), a new anti-VEGF currently indicated in AMD. Case reports suggest that such patients would not need as many injections as in AMD. ASTRID is an open-label, single arm, prospective, multicenter, phase II study. The main objective is to demonstrate the effectiveness in clinical terms after 52 weeks of treatment with aflibercept on the visual acuity of patients affected by CNV in angioid streaks. A specific dosage regimen is designed to achieve maximum efficiency. The patients are followed on a monthly basis until 52 weeks. Six injections are mandatory, the other ones are injected only in case of active CNV.

Withdrawn33 enrollment criteria

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Angioid Streaks

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Withdrawn23 enrollment criteria

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Choroidal NeovascularizationMyopia7 more

Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes. The limitation of this type of treatment is the necessity for frequent intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy in combination with photodynamic therapy can reduce the number of treatments needed with monotherapy while achieving similar visual results. There are ongoing multicenter trials evaluating combination therapy in patients with wet AMD but no similar trial for patients with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on patients with CNV not due to AMD.

Withdrawn26 enrollment criteria

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks...

Angioid StreaksChoroidal Neovascularization

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Unknown status5 enrollment criteria

Antiangiogenic Therapy of CNV Associated With Angioid Streaks

Angioid Streaks of Macula

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to angioid streaks.

Unknown status27 enrollment criteria
1

Need Help? Contact our team!


We'll reach out to this number within 24 hrs